Trials / Completed
CompletedNCT03230630
Plasma Melatonin AND Mortality After Acute Myocardial Infarction
Early-morning Plasma Melatonin Levels Predict Cardiovascular Mortality After Acute Myocardial Infarction
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 732 (actual)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | plasma melatonin levels |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-01-01
- Completion
- 2017-01-01
- First posted
- 2017-07-26
- Last updated
- 2017-07-28
Source: ClinicalTrials.gov record NCT03230630. Inclusion in this directory is not an endorsement.